![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Marksans Pharma Wins FDA Approval for Zyrtec Copycat
Marksans Pharma Wins FDA Approval for Zyrtec Copycat
January 13, 2022
Indian generic drugmaker Marksans Pharma has won FDA approval for its cetirizine hydrochloride tablets.
The antihistamine is indicated for the treatment of allergic rhinitis including sneezing, rhinorrhea, postnasal discharge, watery eyes and running nose.
The 10 mg and 5 mg tablets will be marketed over the counter under store brand labels and is comparable to Johnson & Johnson’s Zyrtec.
Upcoming Events
-
21Oct